Rigel (RIGL) CEO Raul Rodriguez receives 53,915-share RSU equity grant

Rhea-AI Filing Summary

Rigel Pharmaceuticals CEO and President Raul R. Rodriguez reported an equity award on common stock. He acquired a grant of 53,915 shares through a Restricted Stock Unit award at a stated price of $0.00 per share. According to the award terms, these Restricted Stock Units will vest quarterly over three years, with the first vesting date on March 31, 2026. After this grant, Rodriguez directly owns 282,017 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RODRIGUEZ RAUL R

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		53,915(1)	A	$0	282,017	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

	/s/ Raymond Furey (Attorney-in-Fact)	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RIGL CEO Raul R. Rodriguez report on this Form 4?

Raul R. Rodriguez reported acquiring a Restricted Stock Unit award covering 53,915 shares of Rigel Pharmaceuticals common stock. The award was recorded at $0.00 per share, reflecting a grant or equity compensation rather than an open-market purchase.

How will Raul R. Rodriguez’s 53,915 Rigel (RIGL) Restricted Stock Units vest?

The 53,915 Restricted Stock Units granted to Raul R. Rodriguez vest quarterly over three years. The first quarterly vesting is scheduled for March 31, 2026, and subsequent vesting dates continue on a quarterly schedule until the three-year period ends.

How many Rigel (RIGL) shares does Raul R. Rodriguez own after this Form 4 transaction?

Following this equity award, Raul R. Rodriguez is reported as directly owning 282,017 shares of Rigel Pharmaceuticals common stock. This figure reflects his total direct holdings after recording the 53,915-share Restricted Stock Unit grant in the Form 4 filing.

Was cash paid for the 53,915 Rigel (RIGL) shares reported on this Form 4?

The reported transaction lists a price of $0.00 per share for the 53,915 shares, indicating this was a grant or award rather than a cash purchase. It represents equity compensation, not an open-market buying transaction.

What type of security was involved in Raul R. Rodriguez’s RIGL Form 4 transaction?

The transaction involved Common Stock of Rigel Pharmaceuticals delivered through a Restricted Stock Unit award. These RSUs convert into common shares as they vest quarterly over three years, beginning on March 31, 2026, according to the disclosed vesting schedule.